Table 1. Papillary thyroid cancer (PTC) patient specimen analysis (N=19)—characteristics and treatment table.

De-ID	Histology	Age	BRAF status	TERT status	Meta-static disease	Lymph node involve ment	Stage at specimen collection	Staging edition	Specimen collection site	First-line treatment*	Additional lines of treatment*
54	Papillary thyroid carcinoma, macrofollicular variant	<55	Negative	Negative	No	No	PT2N0M0, Stage I	V8	Thyroid	Surgery (thyroidectomy)	N/A
55	Papillary thyroid carcinoma, classical	>55	Positive	Positive	Yes	Yes	pT3bN1bM1, Stage IVC	V8	Lymph Node	Palliative RT to spine mets; Surgery (thyroidectomy, nephrectomy)	N/A
57	Recurrent papillary thyroid carcinoma	<55, >45	Positive	Negative	No	Yes	Recurrent pT4aN1bM0; Stage III	V7	Larynx	Surgery (thyroidectomy, laryngectomy)+RAI	Sorafenib, lenvatinib, vemurafenib, compassionate use pembrolizumab, palliative RT+cyberknife, encorafenib+binimetinib
58	Mult micropapillary carcinomas, classical	<55	Positive	Negative	No	Yes	pT1aN1aM0, Stage II	V8	Thyroid	Surgery (thyroidectomy)+RAI	N/A
59	Papillary thyroid carcinoma	>55	Positive	Negative	No	No	PT1bN0M0, Stage I	V8	Thyroid	Surgery (thyroidectomy)	N/A
60	Metastatic papillary thyroid carcinoma, response to pembro	<55	Positive	Negative	Yes	Yes	Recurrent pT1bN1aMx, Stage I	V8	Thyroid	Surgery (thyroidectomy)+RAI	Surgical bed resection+RAI (recurrence), cediranib, lenvatinib, sorafenib, SRS x 5, compassionate use pembrolizumab, dabrafenib+trametinib, palliative RT
61	Papillary thyroid carcinoma, predominant follicular features	>55	Negative	Negative	No	No	PT1bN0M0, Stage I	V8	Thyroid	Surgery (hemithyroidectomy)	N/A
63	Metastatic papillary thyroid carcinoma; follicular adenoma, lymphocytic thyroiditis	<55	Positive	Negative	No	Yes	pT3N1bM0; Stage I	V8	Thyroid	Surgery (thyroidectomy)+RAI	N/A
64	Metastatic papillary thyroid carcinoma follicular variant; mild lymphocytic thyroiditis	<55	Positive	Negative	No	No	pT1aN0M0, Stage I	V8	Thyroid	Surgery (thyroidectomy and neck dissection)+RAI	N/A
65	Papillary thyroid carcinoma, classical, 6/39 LN positive for carcinoma	<55	Positive	Negative	No	Yes	PT2N1aM0, Stage I	V8	Thyroid	Surgery+RAI	N/A
66	Metastatic thyroid cancer, well-differentiated with follicular architecture.	<55	Negative	Positive	Yes	Yes	pT3N0M1, Stage II	V8	Brain	Surgery (thyroidectomy) in 2009; RAI in 2015 and 2016	Resection+SRS of brain lesions
67	Anaplastic thyroid carcinoma, arising in association with PTC with focal tall cell features	>55	Positive	Negative	Yes	Yes	pT2N1a,cM1, Stage IVC	V8	Central Lymph Node	Surgery+Carbo/Taxol+Radiation	Lenvatinib
69	Metastatic papillary thyroid carcinoma, some tall cells	<55, >45	Positive	Positive	Yes	Yes	pT1bN1bM1, Stage IVC	V7	Neck Lymph Node	Surgery+RAI	Dabrafenib then lenvatinib
70	Locally recurrent multifocal PTC involving the paratracheal region & and central compartment, classical type	<55, <45	Positive	Positive	No	Yes	T3N1bM0, Stage I	V7	Neck Lymph Node	Surgery+RAI	ChemoXRT with cisplatin
74	Papillary (classical) thyroid carcinoma	>55	Positive	Negative	No	PTC is NED	PT1N1bM0, Stage II	V8	Central lymph node	Surgery
75	Papillary thyroid carcinoma, focally invasive into perithyroid soft tissue; lymphocytic thyroiditis and adenomatous nodules; breast cancer	>55	Negative	Positive	No	No	PT3N0M0, Stage II	V8	Thyroid	Surgery
76	Metastatic papillary thyroid carcinoma	<55, >45	Positive	Positive	Yes	Yes	PT4aN1bM1, Stage IVc	V7	Neck Mass	Surgery+RAI	Pembro then lenvatinib then dabrafenib/trametnib
78	Papillary thyroid carcinoma, conventional with focal squamous metaplasia	<55	Positive	Positive	No	No	PT4aN0, Stage I	V8	Thyroid	Surgery+RAI
79	Papillary thyroid carcinoma, follicular variant	>55, >45	Negative	Negative	Yes	Yes	PT4aN1bM0, Stage IVA	V7	Neck Lymph Node	Surgery+RAI	Lenvatinib then entrectinib

^*Patients were treated with current first-line SOC at the time of treatment or clinical trial. Subsequent treatments were chosen based on physician/patient preference.

N/Anot availableRAIradioactive iodine